Literature DB >> 1666930

Recent clinical experience with dronabinol.

T F Plasse1, R W Gorter, S H Krasnow, M Lane, K V Shepard, R G Wadleigh.   

Abstract

Dronabinol, delta-9-tetrahydrocannabinol in sesame oil, has been used for several years as an antiemetic for patients receiving cancer chemotherapy. In combination studies with prochlorperazine, enhancement of efficacy, as measured by duration of episodes of nausea and vomiting and by severity of nausea, has been found. The incidence of psychotropic effects from dronabinol appears to be decreased by concomitant administration of prochlorperazine. In open pilot studies, dronabinol caused weight gain in seven of ten patients with symptomatic HIV infection. In both HIV and cancer patients, dronabinol improved appetite at a dose which was well tolerated for chronic administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666930     DOI: 10.1016/0091-3057(91)90385-f

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  34 in total

Review 1.  The endocannabinoid system: role in energy regulation.

Authors:  Thomas F Gamage; Aron H Lichtman
Journal:  Pediatr Blood Cancer       Date:  2012-01       Impact factor: 3.167

Review 2.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

Review 3.  The marijuana withdrawal syndrome: diagnosis and treatment.

Authors:  Margaret Haney
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

4.  The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.

Authors:  Anne B Need; Richard J Davis; Jesline T Alexander-Chacko; Brian Eastwood; Eyassu Chernet; Lee A Phebus; Dana K Sindelar; George G Nomikos
Journal:  Psychopharmacology (Berl)       Date:  2005-11-18       Impact factor: 4.530

Review 5.  Cannabis.

Authors:  P Robson
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

Review 6.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

7.  Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss.

Authors:  Hee Jung Kim; Angela H Shin; Stanley A Thayer
Journal:  Mol Pharmacol       Date:  2011-06-13       Impact factor: 4.436

Review 8.  Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder.

Authors:  Mariah M Wu; Xinwen Zhang; Melissa J Asher; Stanley A Thayer
Journal:  Brain Res       Date:  2019-09-17       Impact factor: 3.252

Review 9.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.

Authors:  Joyonna C Gamble-George; Jordan R Conger; Nolan D Hartley; Prerna Gupta; Joshua J Sumislawski; Sachin Patel
Journal:  Psychopharmacology (Berl)       Date:  2013-03-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.